Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968184 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
A Phase 3 study, sponsored by KBP Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 652
- Enrollment target
NCT04968184 is a Phase 3 study that was terminated before completion, run by KBP Biosciences. The registered enrollment target is 652 participants.
The verdict
NCT04968184, a Phase 3 study, was terminated before completion, sponsored by KBP Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 652 participants
- Enrollment target
Study Summary
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[eGFR {EPI}\] ≥15 to ≤44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and \<180 mm Hg and taking 2 or more antihypertensive medications.
Interventions
- DRUG Placebo
- DRUG KBP-5074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2024-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04968184
The ClinicalTrials.gov registry entry for NCT04968184 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 652 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KBP Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04968184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04968184 about?
NCT04968184 is a clinical study titled "Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)". This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate ...
What is the current status of trial NCT04968184?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 652 participants. The study started on 2021-11-05. Estimated completion is 2024-07-10.
What interventions are being tested in trial NCT04968184?
The interventions under investigation include: Placebo (DRUG), KBP-5074 (DRUG).
Who is sponsoring clinical trial NCT04968184?
This trial is sponsored by KBP Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.